The total return over the past 12 months is -5.13% vs. +16.94% for the S&P 500. So far it's up -5.27% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (5.13%) | (18.32%) | +6.13% | +2.47% | N/A | N/A |
| Total Return CAGR | (5.13%) | (18.32%) | +6.13% | +2.47% | N/A | N/A |
| Revenue CAGR | +1.35% | +10.51% | +13.71% | +10.53% | N/A | N/A |
| Net Income CAGR | (41.69%) | (8.32%) | +49.69% | +18.90% | N/A | N/A |
| EPS CAGR | (37.86%) | (14.15%) | +134.23% | N/A | N/A | N/A |
| Free Cash Flow CAGR | +36.28% | +15.03% | +23.90% | +28.64% | N/A | N/A |
| Operating Cash Flow CAGR | +15.63% | +12.14% | +18.01% | +19.89% | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Amphastar Pharmaceuticals, Inc. (AMPH)
| Year | Start price | End price | AMPH Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $26.78 | $25.37 | (5.27%) | +14.51% | (19.78%) |
| 2025 | $37.13 | $26.78 | (27.88%) | +17.72% | (45.60%) |
| 2024 | $61.85 | $37.13 | (39.97%) | +24.89% | (64.86%) |
| 2023 | $28.02 | $61.85 | +120.74% | +26.19% | +94.55% |
| 2022 | $23.29 | $28.02 | +20.31% | (18.17%) | +38.48% |
| 2021 | $20.11 | $23.29 | +15.81% | +28.74% | (12.93%) |
| 2020 | $19.29 | $20.11 | +4.25% | +18.37% | (14.12%) |
| 2019 | $19.90 | $19.29 | (3.07%) | +31.22% | (34.29%) |
| 2018 | $19.24 | $19.90 | +3.43% | (4.56%) | +7.99% |
| 2017 | $18.42 | $19.24 | +4.45% | +21.70% | (17.25%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
